Cellmid 2018 Annual Report 15
Principal activities and significant changes in nature of activities
The principal activities of the Group during the financial year were:
Midkine Business: The development and commercialisation of diagnostic and therapeutic products for the management
of diseases such as cancer and various chronic inflammatory conditions by targeting midkine (Lyramid Limited and Kinera
Limited); and
Consumer Health Business: The development and sale of over-the-counter (OTC) and cosmetic treatments to alleviate
excessive and abnormal hair loss and re-establish the natural hair growth cycle (Advangen Limited)
There were no significant changes in the nature of the Group’s principal activities during the financial year.
Operating results
The operating results for the Group continued to improve during the 2018 financial year. Revenue and Other Income for the
Group increased 23% to $6,834,924 (2017: $5,560,121) during the reporting period, with a 26% increase in Consumer Health
revenue to $5,647,930 (2017: $4,496,338). Consolidated loss was down 17% to $3,732,615 after providing for income tax
(2017: $4,482,273 loss). An R&D tax credit of $946,963 was received during the reporting period (2017: $831,408).
Review of operations
The Group achieved several major commercial milestones during FY2018 for the Consumer Health Business (Advangen
Limited) in Australia, Japan, USA and China. In Japan, the Group’s sales in television shopping channel QVC continued to
increase and the first Advangen concept store was opened in October 2017 in Ginza, Tokyo. In Australia distribution rights for
a new product range, Fillerina®, have been secured to optimise existing sales channels. In the USA the Group signed retail
partnerships with Neiman Marcus, Bloomingdales and Soft Surroundings during the reporting period. In China, import permits
for the Group’s Japanese brands were issued in August 2017 and a distribution agreement was signed with Beijing Fukangren
Biopharma in May 2018.
The Group’s Midkine Business, Lyramid Limited and Kinera Limited, continued the preclinical development programs and
demonstrated efficacy in new disease models. The Group has formed collaborations, which resulted in the development of
novel intellectual property and filing of patent applications. The scientific developments around the Group’s key midkine asset
portfolio resulted in a publication in Nature, the highest ranked scientific journal. In addition to receiving the R&D tax credit of
$946,963 the Group received an Innovation Connections Grant to the value of $110,000 from the Federal Government for its
research into chronic kidney disease.
Mr Lee Tamplin Company Secretary (Appointed 6 September 2018)
Qualifications BA (Hons) Financial Services, Bournemouth University United Kingdom, Diploma of Financial
Planning, Graduate of the Australian Institute of Company Directors and Member of the
Governance Institute of Australia
Experience 20 years’ experience in financial services in both Australia and UK. Company Secretary for a
number of ASX listed, NSX listed and proprietary companies.
Mr Raymond Ting Company Secretary (Resigned 6 September 2018)
Qualifications B.Com, University of Western Australia, Graduate Diploma of Applied Corporate Governance,
Member of The Institute of Chartered Accountants Australia and New Zealand
Experience A Chartered Accountant and Company Secretary with accounting and secretarial experience in
public listed companies, unlisted property fund managers, property developers, multi-national
engineering firms and large private companies.